Skip to main content
Fig. 3 | BMC Medical Genomics

Fig. 3

From: SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma

Fig. 3

DLBCL Cell Cycle Experiment. The cell cycle results showed that compared with the OCI-LY1 + SLC27A2-siRNA-817 group, the G1 phase cells were significantly reduced, the S phase cells were significantly increased, and the G2 phase cells were significantly increased (A, B). Therefore, low expression of SLC27A2 significantly promoted the progression of the DLBCL cell cycle

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us